Dr. Jason Brown, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Yale University School of Medicine (2015)
- Years since graduation
- 11
- In the NPI registry since
- 2015
- Medicare patients seen, 2024
- 120
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2015Medical school: Yale University School of Medicine
- 2015Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
OH license 35.141962 -
Student in an Organized Health Care Education/Training Program
MI license 4301106976
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Uh Cleveland Medical Center Cleveland, OH
- University Hospitals Ahuja Medical Center Beachwood, OH
- Parma Community General Hospital Parma, OH
- Uh St John Medical Center Westlake, OH
- University Hospitals - Elyria Medical Center Elyria, OH
Medical groups
- University Hospitals Medical Group Inc (2,294 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 120
- Services billed
- 455
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 183 | 96 |
| New patient office or other outpatient visit, 60-74 minutes | 33 | 33 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Ann Arbor, MI | 273 |
| Abiraterone Acetate | 213 |
| Orgovyx (relugolix) | 182 |
| Ondansetron Hcl Other prescribers in Ann Arbor, MI | 74 |
| Prochlorperazine Maleate Other prescribers in Ann Arbor, MI | 72 |
| Erleada (apalutamide) | 57 |
| Olanzapine Other prescribers in Ann Arbor, MI | 52 |
| Dexamethasone Other prescribers in Ann Arbor, MI | 40 |
| Cabometyx (cabozantinib s-malate) | 31 |
| Gabapentin Other prescribers in Ann Arbor, MI | 26 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 16 companies reported 55 payments worth $19,978 in total to this clinician.
| Janssen Biotech, Inc. | $7,093 |
|---|---|
| Merck Sharp & Dohme LLC | $4,343 |
| AstraZeneca Pharmaceuticals LP | $4,263 |
| Astellas Pharma US Inc | $2,100 |
| Janssen Scientific Affairs, LLC | $1,110 |
| Pfizer Inc. | $462 |
| Caris Mpi, Inc. | $168 |
| AstraZeneca UK Limited | $88.09 |
| Consulting Fee | $12,991 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $4,270 |
| Food and Beverage | $1,577 |
| Travel and Lodging | $1,140 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Jun 4, 2025 | Compensation for services other than consulting (speaking, faculty) WELIREG · ONCOLOGY | $4,270 |
| AstraZeneca Pharmaceuticals LP Oct 1, 2025 | Consulting Fee IMFINZI · Oncology | $4,100 |
| Janssen Biotech, Inc. Mar 14, 2025 | Consulting Fee ERLEADA; AKEEGA · Oncology | $3,788 |
| Astellas Pharma US Inc Oct 27, 2025 | Consulting Fee Padcev · Oncology | $2,100 |
| Janssen Biotech, Inc. Oct 3, 2025 | Consulting Fee ERLEADA · Oncology | $1,263 |
| Janssen Scientific Affairs, LLC Jun 5, 2025 | Consulting Fee ERLEADA · Oncology | $1,110 |
| Janssen Biotech, Inc. Feb 20, 2025 | Travel and Lodging ERLEADA; AKEEGA · Oncology · travel to HOUSTON, TX · in-kind | $684 |
| Janssen Biotech, Inc. Apr 4, 2025 | Consulting Fee ERLEADA; AKEEGA · Oncology | $631 |
| Janssen Biotech, Inc. Mar 4, 2025 | Travel and Lodging ERLEADA; AKEEGA · Oncology · travel to HOUSTON, TX · in-kind | $263 |
| Janssen Biotech, Inc. Mar 4, 2025 | Travel and Lodging ERLEADA; AKEEGA · Oncology · travel to HOUSTON, TX · in-kind | $150 |
All 12 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Astellas Pharma US Inc Oct 27, 2025 | Consulting Fee Padcev · Oncology | $2,100 |
| Astellas Pharma Europe LTD Oct 20, 2025 | Travel and Lodging Vyloy · Oncology · travel to Berlin, Germany | $17.90 |
| Janssen Biotech, Inc. Oct 3, 2025 | Consulting Fee ERLEADA · Oncology | $1,263 |
| AstraZeneca Pharmaceuticals LP Oct 1, 2025 | Consulting Fee IMFINZI · Oncology | $4,100 |
| Janssen Scientific Affairs, LLC Jun 5, 2025 | Consulting Fee ERLEADA · Oncology | $1,110 |
| Merck Sharp & Dohme LLC Jun 4, 2025 | Compensation for services other than consulting (speaking, faculty) WELIREG · ONCOLOGY | $4,270 |
| Merck Sharp & Dohme LLC Jun 4, 2025 | Travel and Lodging WELIREG · ONCOLOGY · travel to Independence, OH | $25.00 |
| Janssen Biotech, Inc. Apr 4, 2025 | Consulting Fee ERLEADA; AKEEGA · Oncology | $631 |
| Janssen Biotech, Inc. Mar 14, 2025 | Consulting Fee ERLEADA; AKEEGA · Oncology | $3,788 |
| Janssen Biotech, Inc. Mar 4, 2025 | Travel and Lodging ERLEADA; AKEEGA · Oncology · travel to HOUSTON, TX · in-kind | $263 |
| Janssen Biotech, Inc. Mar 4, 2025 | Travel and Lodging ERLEADA; AKEEGA · Oncology · travel to HOUSTON, TX · in-kind | $150 |
| Janssen Biotech, Inc. Feb 20, 2025 | Travel and Lodging ERLEADA; AKEEGA · Oncology · travel to HOUSTON, TX · in-kind | $684 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 5 companies. The companies reported $489,303 in research payments for these studies, mostly to the institutions running them.
- A phase 2 multicohort openlabel multicenter clinical study evaluating the efficacy and safety of disitamab vedotin RC48ADC alone or in combination with pembrolizumab in subjects with locallyadvanced unresectable or me…
Seagen Inc. - A phase 2 multi cohort open label multicenter clinical study evaluating the efficacy and safety of disitamab vedotin RC48 adc in subjects with HER2 expressing locally advanced unresectable or metastatic urothelial car…
Seagen Inc. - Firstinhuman fih openlabel phase 1 dose escalation and expansion study designed to evaluate the safety tolerability pk pd and preliminary clinical activity of PF07826390 as a single agent or in combination treatment f…
Pfizer Inc. - A phase 3 randomized doubleblind placebocontrolled study of mevrometostat PF06821497 with enzalutamide in metastatic castrationsensitive prostate cancer MEVPRO3
Pfizer Inc. - Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)
AbbVie Inc. · Active, not recruiting · NCT06632951 - A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy versus Perioperative Placebo Neoadjuvant Chemotherapy in Cisplatin-Eligible Participants with Muscle…
Merck Sharp & Dohme LLC - A study of enfortumab vedotin ASG22CE as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer
Pfizer Inc. - A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder
Janssen Research & Development, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.